# Intrathecal Drug Delivery Systems

## Introduction

Intrathecal drug delivery systems (IDDS) provide targeted medication administration directly into the cerebrospinal fluid (CSF), bypassing the blood-brain barrier and achieving effective analgesia at a fraction of the systemic dose. This approach is a cornerstone of interventional pain management for patients with severe, refractory chronic pain and cancer pain who have failed or cannot tolerate systemic medications. Understanding pump mechanisms, drug pharmacology, trialing protocols, dose titration, and complication management is essential for the pain medicine specialist.

## Pump Mechanisms

### Fixed-Rate Pumps

Fixed-rate (constant-flow) pumps, such as the Codman Medstream, deliver medication at a rate determined by the pump's internal mechanics. There is no external programming capability, so dose adjustments require changes in the drug concentration within the reservoir. The simpler design and lower cost are offset by limited flexibility, and these pumps are rarely used in modern practice because dose titration cannot be performed without a reservoir refill.

### Programmable Pumps

Programmable pumps, such as the Medtronic SynchroMed II, are the current standard of care. They contain a titanium reservoir (available in 20 mL or 40 mL capacities), a battery-powered peristaltic pump, and an electronic module. Dose adjustments are made non-invasively via a telemetry programmer that communicates with the pump through radiofrequency. The pump can deliver medication in continuous, flex-dose, or patient-activated bolus modes. Battery life is approximately seven years, depending on flow rate and programming. The reservoir is refilled percutaneously through a self-sealing silicone septum accessed with a non-coring Huber needle, typically every one to six months depending on drug concentration and flow rate.

### Catheter Components

A silicone or polyurethane catheter extends from the pump to the intrathecal space. The catheter tip is positioned at the target spinal level -- T10-L1 for lower body pain, C5-T2 for upper body pain. It is secured with an anchor at the fascial entry point and tunneled subcutaneously to the pump pocket.

<image>Cross-sectional anatomical and device illustration showing an intrathecal drug delivery system in situ, with a programmable pump implanted in the left lower abdominal wall subcutaneous pocket, a catheter tunneled subcutaneously around the flank to the lumbar spine, entering the intrathecal space at L3-L4, and the catheter tip positioned at the T10 level within the thecal sac, with a magnified inset showing the pump internals including the drug reservoir, peristaltic roller mechanism, battery, electronic module, and the self-sealing refill septum accessed by a non-coring Huber needle</image>

## Drug Selection

### First-Line Agents (PACC Guidelines)

#### Morphine

Morphine is the most widely used intrathecal opioid and is FDA-approved for intrathecal delivery. Its hydrophilic nature results in broad rostral CSF spread, providing analgesic coverage across multiple dermatomes. The starting dose for opioid-naive patients is 0.1-0.5 mg/day, titrated to effect. The maximum recommended dose is 15 mg/day, as higher doses are associated with an increased risk of catheter-tip granuloma formation. Side effects include nausea, pruritus, urinary retention, edema, hormonal suppression, and respiratory depression.

#### Ziconotide (Prialt)

Ziconotide is an FDA-approved synthetic N-type calcium channel blocker derived from cone snail venom (omega-conotoxin). It works through a non-opioid mechanism: blocking presynaptic N-type voltage-gated calcium channels in the dorsal horn, which inhibits neurotransmitter release. Ziconotide does not cause tolerance, respiratory depression, or hormonal effects. The starting dose is 0.5-1.2 mcg/day, titrated slowly (no more than 0.5-1.0 mcg/day increase per week) up to a maximum of 19.2 mcg/day. Side effects include dizziness, nausea, confusion, gait disturbance, and psychiatric symptoms (including psychosis and suicidal ideation at higher doses), necessitating careful neuropsychiatric monitoring. It can be used as monotherapy or in combination with other intrathecal agents.

### Second-Line Agents

#### Bupivacaine

Bupivacaine is a local anesthetic that provides segmental analgesia through sodium channel blockade. It is commonly used in combination with morphine or ziconotide for synergistic effect. The starting dose is 1-4 mg/day, with a maximum of approximately 30 mg/day. Side effects include hypotension, motor weakness, and urinary retention at higher doses. Its lipophilic nature produces a more localized effect near the catheter tip compared to the broad spread of morphine.

#### Hydromorphone

Hydromorphone is a semi-synthetic opioid, more lipophilic than morphine, and is used as an alternative when morphine is not tolerated. The intrathecal equianalgesic ratio is approximately 5:1 (morphine to hydromorphone), and the starting dose is 0.02-0.1 mg/day.

### Third-Line and Adjunctive Agents

#### Baclofen

Baclofen is FDA-approved for intrathecal treatment of severe spasticity associated with cerebral palsy, multiple sclerosis, and spinal cord injury. It acts as a GABA-B receptor agonist and is also used off-label for pain management. The starting dose is 25-50 mcg/day, titrated based on spasticity assessment. A critical safety concern: abrupt withdrawal from intrathecal baclofen is life-threatening and can cause hyperthermia, rhabdomyolysis, seizures, multiorgan failure, and death.

#### Clonidine

Clonidine is an alpha-2 adrenergic agonist with analgesic effects at the spinal cord level. It is used in combination with opioids or as part of multi-drug mixtures at doses of 20-100 mcg/day. Side effects include hypotension, bradycardia, and sedation.

## Trialing Protocols

### Purpose

A trial is performed to assess analgesic response and tolerability before committing to permanent pump implantation. The goal is to demonstrate that intrathecal drug delivery provides meaningful pain relief and functional improvement.

### Trial Methods

There are several approaches. A single-shot intrathecal injection delivers a bolus of morphine (0.1-0.5 mg) or ziconotide via lumbar puncture, and pain is assessed over the expected duration of action. A continuous intrathecal infusion trial uses an externalized catheter connected to an external pump to deliver medication over 3-7 days, providing a more physiologic assessment that better replicates the chronic delivery model. Some practitioners use an epidural catheter trial as a surrogate, though this is less specific than true intrathecal delivery. A positive trial is defined as 50% or greater reduction in pain with improved function and acceptable side effects.

### Considerations

Single-shot trials are simpler but less predictive of long-term outcomes. Continuous infusion trials better replicate chronic delivery but carry higher infection risk due to the externalized catheter. Ziconotide trials require slow titration over days to weeks -- a single bolus is insufficient to assess response. Respiratory status must be monitored closely during opioid trials, particularly in opioid-naive patients.

## PACC Guidelines (Polyanalgesic Consensus Conference)

The Polyanalgesic Consensus Conference (PACC) provides evidence-based algorithms for intrathecal drug selection organized by pain type and treatment line.

| PACC Line | Nociceptive Pain | Neuropathic Pain | Mixed Pain |
|-----------|-----------------|-----------------|-----------|
| Line 1 | Morphine or ziconotide monotherapy | Ziconotide (preferred); morphine | Morphine or ziconotide monotherapy |
| Line 2 | Morphine + bupivacaine; hydromorphone | Morphine + bupivacaine; hydromorphone; ziconotide + opioid | Morphine + bupivacaine; hydromorphone |
| Line 3 | Opioid + clonidine; bupivacaine + clonidine | Opioid + clonidine; bupivacaine + clonidine | Opioid + clonidine; bupivacaine + clonidine |
| Line 4+ | Fentanyl/sufentanil; baclofen (if spasticity) | Fentanyl/sufentanil; experimental agents | Fentanyl/sufentanil; baclofen |

For Line 1 recommendations, nociceptive pain is treated with morphine or ziconotide as monotherapy, neuropathic pain with ziconotide as first choice (morphine as alternative), and mixed pain with morphine or ziconotide monotherapy. Line 2 recommendations include morphine plus bupivacaine combinations, hydromorphone monotherapy, and ziconotide plus opioid combinations. Line 3 and beyond adds clonidine to opioid-based regimens, bupivacaine plus clonidine combinations, fentanyl or sufentanil (more lipophilic opioids used less commonly due to limited spread), and baclofen for co-existing spasticity.

<image>Flowchart diagram illustrating the PACC Polyanalgesic Consensus Conference algorithm for intrathecal drug selection, with three columns for nociceptive pain, neuropathic pain, and mixed pain, showing Line 1 through Line 4 recommendations in descending order, with morphine and ziconotide as monotherapy at Line 1, combination therapies with bupivacaine and hydromorphone at Line 2, addition of clonidine and alternative opioids at Line 3, and experimental agents at Line 4, with arrows connecting each line to the next when prior therapy fails, and notation of evidence grades for each recommendation</image>

## Dose Titration

### General Principles

The starting point should always be the lowest effective dose, with slow upward titration. Opioid dose increases should not exceed 10-20% per adjustment, and adequate time between adjustments (3-7 days for opioids) is needed to assess steady-state effects. Ziconotide titration must be particularly cautious -- no more than 0.5 mcg/day increase per week -- to avoid neuropsychiatric side effects. Pain scores, functional status, side effects, and oral opioid consumption should all be documented at each visit.

### Opioid Rotation

If tolerance develops or side effects limit dose escalation, rotating to a different intrathecal opioid can be effective. When rotating, the calculated equianalgesic dose should be reduced by 25-50% to account for incomplete cross-tolerance. Adding a non-opioid adjunct (bupivacaine, clonidine, or ziconotide) may restore efficacy without requiring opioid dose escalation.

### Refill Protocols

Refills are performed using strict aseptic technique with a non-coring Huber needle. Template kits that snap onto the pump facilitate accurate septum access. The pump residual volume should be verified against the expected volume to detect catheter malfunction. Documentation should include drug concentration, volume instilled, flow rate, and reservoir alarm settings.

## Complications

### Catheter-Tip Granuloma (Inflammatory Mass)

Catheter-tip granulomas are sterile inflammatory masses that form at the catheter tip within the intrathecal space, occurring in 3-5% of patients on chronic intrathecal opioid therapy. Risk factors include high opioid concentration, high daily dose (particularly morphine above 10-15 mg/day), and catheter tip placement in the thoracic spine. Patients present with new neurological deficits (weakness, sensory changes, bowel or bladder dysfunction), escalating pain despite dose increases, or a change in pain pattern. Diagnosis is made by MRI with gadolinium showing an enhancing mass at the catheter tip. Management involves reducing the opioid dose or switching to ziconotide (which does not cause granulomas), and surgical decompression may be required if a neurological deficit is present. Ziconotide should be considered in patients at high granuloma risk.

### Withdrawal Syndromes

Opioid withdrawal occurs with pump malfunction, catheter occlusion, or an empty reservoir. Symptoms include anxiety, diaphoresis, tachycardia, muscle cramping, and nausea, and management requires oral opioid rescue and urgent pump assessment. Baclofen withdrawal is a medical emergency that can progress to hyperthermia, rhabdomyolysis, disseminated intravascular coagulation, seizures, and death within 24-48 hours. Prevention requires established alarm settings on programmable pumps, strict adherence to regular refill schedules, and thorough education of patients and caregivers on warning signs.

### Other Complications

Infection ranges from meningitis (rare but serious) to pump pocket infection and catheter tract infection. CSF leak and post-dural puncture headache can occur during trial or permanent catheter placement. Catheter malfunction -- kinking, disconnection, migration, or occlusion -- is diagnosed by catheter access study with dye injection under fluoroscopy. Pump pocket seroma is common in the early postoperative period and is usually self-resolving. Chronic intrathecal opioids suppress the hypothalamic-pituitary-gonadal axis, causing hypogonadism, decreased libido, and osteoporosis. Peripheral edema, particularly with morphine, involves histamine release and ADH effects. Respiratory depression carries the highest risk in opioid-naive patients during trial and initial titration, making monitoring protocols essential.

## Clinical Pearls

Ziconotide is the only intrathecal analgesic that does not cause tolerance, respiratory depression, or catheter-tip granulomas, and it should be considered first-line for neuropathic pain and in patients at high risk for granuloma formation. Baclofen withdrawal is a life-threatening emergency; every patient on intrathecal baclofen must have a documented emergency plan, and pump refill appointments must never be missed. When pain escalates in a patient with an intrathecal pump, catheter-tip granuloma should always be considered before simply increasing the opioid dose, since dose escalation may actually worsen the granuloma. A high index of suspicion for catheter malfunction is warranted when the pump reservoir volume at refill differs significantly from the calculated residual; a catheter access study should be performed. Intrathecal drug delivery is most cost-effective for patients with a life expectancy greater than 3-6 months due to the upfront cost of implantation -- for cancer pain patients, this threshold is critical in treatment planning.

## References

1. Deer TR, Pope JE, Hayek SM, et al. The Polyanalgesic Consensus Conference (PACC): Recommendations on intrathecal drug infusion systems best practices and guidelines. *Neuromodulation*. 2017;20(2):96-132.
2. Yaksh TL, Hassenbusch S, Burchiel K, Hildebrand KR, Page LM, Coffey RJ. Inflammatory masses associated with intrathecal drug infusion: A review of preclinical evidence and human data. *Pain Med*. 2002;3(4):300-312.
3. Coffey RJ, Owens ML, Broste SK, et al. Mortality associated with implantation and management of intrathecal opioid drug infusion systems to treat noncancer pain. *Anesthesiology*. 2009;111(4):881-891.
4. Pope JE, Deer TR, Bruel BM; intrathecal drug delivery for pain: A review of recent advances and future developments. *Expert Rev Neurother*. 2016;16(12):1461-1474.